Close Menu

University of British Columbia

The antibody profile could potentially be used to improve stratification of patient cohorts in clinical trials or as a point-of-care test to determine whether a patient needs vaccination, Reinhard Hiller, managing director of CPGR, told ProteoMonitor.

The technique allows for the first time the proteome-wide study of protein carboxy termini, according to one of its developers.

The recruitment effort seeks researchers to fill two new positions in metabolic engineering and synthetic biology; two new positions in computational tools and technology development; and two existing positions in chemical, molecular and systems biology, and bioengineering.

CPGR will be developing multiplex protein array-based antibody profiling assays and related bioinformatic analysis methods for the project with the ultimate aim of creating a biomarker signature that can be used for companion diagnostic purposes.

The partners aim to identify biomarkers that may predict how patients react to seasonal influenza vaccinations.

The algorithm, which was developed in collaboration with researchers in the Mathematics of Information Technology and Complex Systems groups at the University of British Columbia and Simon Fraser University, will allow Kinexus to do high-resolution mapping of an estimated 25 million kinase-substrate interactions, said a company official.

Genome British Columbia said today that a team comprising researchers from Canada, the US, and France is embarking on an effort to sequence and develop genetic tools for the sunflower genome.

The $3.2 million project funded by DOD and Canada will focus on using bacterial genomics to develop RDX degradation tools.

Two programs guided by Canadian funding and research will try to use poplars and pines for biofuels.

Eiger Biopharma licenses Hep C Rx IP from Stanford; TapImmune buys vaccine IP from UBC; Acetylon Pharma closes $7.25M series A to commercialize Dana-Farber, Harvard HDAC inhibitors; EMD Serono and MD Anderson ink clinical trial pact; U of Queensland's IMBcom licenses HGH receptor cell lines to Prolor Biotech

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

Time magazine looks into how liquid biopsies are changing cancer care.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.